“I believe this is the largest and most representative genomic study of advanced prostate cancer in men of African and European ancestry,” said Dr. Brandon Mahal, assistant professor of radiation oncology at Sylvester and the study’s senior author.
Newswise — MIAMI, FLORIDA (May 24, 2023) – Why do men of African ancestry die from prostate cancer more frequently than other men and experience the greatest burden of advanced prostate disease globally?
A large-scale retrospective analysis by researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, suggests that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestry.
The study of almost 13,000 men with advanced prostate cancer, published May 24 in The Lancet Digital Health is one of the most comprehensive studies to date of prostate cancer disparities between men of these ethnicities.
“I believe this is the largest and most representative genomic study of advanced prostate cancer in men of African and European ancestry,” said Dr. Brandon Mahal, assistant professor of radiation oncology at Sylvester and the study’s senior author.
“The data,” he continued, “clearly show no notable differences in genetic mutations between the ancestries that we would target for treatment, which suggests these mutations probably are not driving disparities in advanced prostate cancer.”
Mahal and coauthors found that men of African ancestry – despite being at higher risk for developing aggressive prostate disease – are less likely to get comprehensive genetic profiling of their tumors early in treatment. That means they do not benefit as often as their European counterparts from sophisticated testing that can guide genetically targeted therapy and lead to improved patient outcomes. Instead, they may endure other, sometimes less-effective treatments as their cancer progresses.
African ancestry men also were less likely than European ancestry men to go into clinical trials for prostate cancer, which typically involve newer, more effective treatments for aggressive disease, Mahal noted.
“We’ve known for a couple of decades that prostate cancer disparities are some of the largest disparities we see across all cancer types. This research can help focus our efforts on what’s needed to address these disparities,” he said, adding that future studies should not ignore examining genomics.
“While this study looked at advanced prostate cancer and diminished the focus on genomics as the reason for disparities, there is still a reason to study the role of genomics in men’s risk for developing prostate cancer,” Mahal concluded.
Acknowledgements
Sylvester worked in collaboration with researchers from Foundation Medicine, University of Michigan and Harvard Medical School on this study.
Contributors
The complete list of authors is included with the study.
Funding
The study was funded by the American Society for Radiation Oncology, Department of Defense, Flatiron Health, Foundation Medicine, Prostate Cancer Foundation and Sylvester Comprehensive Cancer Center.
Declaration of Interests
SS, JKL, JAM, JH, JYN, RM, RG, ABS, GMF, JM and JV are employed by Foundation Medicine, with an equity interest in Roche. BAM is funded by the Prostate Cancer Foundation, American Society for Radiation Oncology, Department of Defense and National Institutes of Health, as well as generous donations from Sylvester Comprehensive Cancer Center. All other authors declare no competing interests. A full list of authors is available here.
DOI: https://doi.org/10.1016/S2589-7500(23)00053-5
# # #
RSS